Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling

por Hintzen, Gabriele, Dulat, Holger J., Rajkovic, Erich
Publicado 2022

Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity

por Ellwanger, Kristina, Reusch, Uwe, Fucek, Ivica, Wingert, Susanne, Ross, Thorsten, Müller, Thomas, Schniegler-Mattox, Ute, Haneke, Torsten, Rajkovic, Erich, Koch, Joachim, Treder, Martin, Tesar, Michael
Publicado 2019

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors

por Wingert, Susanne, Reusch, Uwe, Knackmuss, Stefan, Kluge, Michael, Damrat, Michael, Pahl, Jens, Schniegler-Mattox, Ute, Mueller, Thomas, Fucek, Ivica, Ellwanger, Kristina, Tesar, Michael, Haneke, Torsten, Koch, Joachim, Treder, Martin, Fischer, Wolfgang, Rajkovic, Erich
Publicado 2021